Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any ...

A landmark clinical trial has discovered that omalizumab, marketed as Xolair, provides more effective treatment for multiple food allergies than the current standard approach of oral immunotherapy ...

Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair; Genentech, Novartis). Omlyclo was approved to treat the same conditions as Xolair. The FDA approved Celltrion’s omalizumab ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...

New research, led by Johns Hopkins Children’s Center investigators and sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), finds that ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

SAN DIEGO — Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at the 2025 American Academy of Allergy, Asthma & Immunology ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...

In all, 36% of children treated with omalizumab (Xolair) for a year successfully ate full servings of allergy-triggering foods, according to phase 2 trial results presented Sunday at a meeting of ...